Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
11
Mins
19 Dec 2022
Nothing About Me Without Me: Shared Decision-Making in Chronic Hepatitis B
Hepatitis B affects more than 296 million people worldwide, according to the World Health Organization (WHO). More than 1.5 million new infections occur each year, despite the availability of safe and effective vaccines.
Challenging the postcode health lottery
A postcode can determine health outcomes more than genetics. How can pharma help to solve the postcode lottery?
10
Mins
19 Dec 2022
Prevalence of SARS-CoV-2 Cellular and Humoral Immunity Amongst Patients on Dialysis After the First Vaccination Campaign
Global immunisation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the standard-of-care in preventing COVID-19…
8
Mins
19 Dec 2022
Anti-TNF Treatment in Crohn’s Disease Complicated by Intra-abdominal Abscess
Excess production of TNF-α leads to chronic inflammation and tissue damage in immune-mediated inflammatory diseases (IMID) such as Crohn’s Disease (CD), rheumatoid arthritis, and psoriasis. The introduction of anti-TNF agents revolutionised therapy for patients with IMIDs, and two anti-TNFs are currently approved for use in CD in Europe: infliximab and adalimumab.
December 2022
EMJ Gastroenterology 11 [Supplement 8] 2022
This mini-review is the fourth in a series exploring TNF inhibitors in treating immune-mediated inflammatory disease. Specifically, this mini-review summarises the evidence of anti-TNFs in Crohn’s disease (CD) complicated by intra-abdominal abscess.
16 Dec 2022
Virtual Reality to Reality - The Impact of Charities on Health
Jonathan is joined by film producer Peter Samuelson for an in-depth discussion on the work carried out by his award-winning charities. Listen now!
Turning patient insights into action
Pharma endeavours to drive positive action from patient insights. Read to find out how they could improve their methodologies and outcomes.
14 Dec 2022
Using Behavioral Science to Help Understand Vaccine Hesitancy
This video details Graves’ research on vaccine hesitancy and the psychological and sociocultural factors behind it. Learn ways to identify and overcome vaccine hesitancy by using valuable, research-based insights and strategies.
Mitigating the rare disease RWD deficit
RWD for rare diseases is scarce, but pharma can work to leverage existing processes and build trust to enhance the scope of available data.
Sales reps, MSLs and the future of CX
In this episode, the team chat to James Harper, Founder and Managing Director, Twentyeightb, about pharma sales, MSLs and more.
←
1
2
3
…
315
316
317
318
319
320
321
…
1,004
1,005
1,006
→